Therefore, in this study, we measured serum tau proteins, including tau proteins within the circulating EX fraction, in AD patients and age-matched controls at baseline and over disease progression to evaluate both the diagnostic efficacy of tau and the association with the severity of cognitive dysfunction. The gene discussed is MAPT; the disease is Alzheimer disease.